Cinacalcet is an agonist at Ca2+-sensing receptors that is clinically used to treat secondary hyperparathyroidism with chronic kidney disease. Cinacalcet also displays anti-fibrotic activity. This compound decreases levels of parathyroid hormone (PTH), increases adiponectin secretion, and lowers oxidative stress. This compound increases sensitivity of Ca2+-sensing receptors to serum Ca2+ levels. In vivo, cinacalcet decreases renal epithelial-to-mesenchymal transition (EMT) and prevents the development of renal fibrosis.